Results 101 to 110 of about 396 (132)
Tissue Distribution and Receptor Activation by Somapacitan, a Long Acting Growth Hormone Derivative [PDF]
International Journal of Molecular Sciences, 2020 Somapacitan is a long-acting, once-weekly, albumin-binding growth hormone (GH) derivative. The reversible albumin-binding properties leads to prolonged circulation half-life. Here, we investigated and compared somapacitan with human GH on downstream receptor signaling in primary hepatocytes and hepatocellular models and using isothermal titration ...
Peter Thygesen +2 more
exaly +5 more sources
Once-Weekly Somapacitan Is Effective and Well Tolerated in Adults With GH Deficiency: A Randomized Phase 3 Trial [PDF]
Journal of Clinical Endocrinology and Metabolism, 2020 Abstract Context Growth hormone (GH) replacement requires daily GH injections, which is burdensome for some adult patients with GH deficiency (AGHD). Objective To demonstrate efficacy and safety of somapacitan, a once-
Murray Bruce Gordon +2 more
exaly +5 more sources
Somapacitan in Children Born Small for Gestational Age: 4-Year Results From Phase 2
European Journal of EndocrinologyAbstract Objective Evaluate long-term efficacy, safety, and tolerability of once-weekly somapacitan, a long-acting growth hormone (GH) derivative, in children born small for gestational age (SGA) with short stature, including after switching from daily GH.
Anders Juul +2 more
exaly +5 more sources
Clinical EndocrinologyAbstract Objective Somapacitan is a long‐acting growth hormone (GH) derivative developed for the treatment of GH deficiency (GHD). This study evaluates the efficacy and tolerability of somapacitan in Japanese children with GHD after 104 weeks of treatment and after switch from daily GH.
Jun Mori +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Canadian Journal of Health Technologies, 2023
CADTH recommends that Sogroya should be reimbursed by public drug plans for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency [GHD]) if certain conditions are met. Sogroya should only be covered to treat children who are at least 2.5 ...
openaire +1 more source
CADTH recommends that Sogroya should be reimbursed by public drug plans for the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency [GHD]) if certain conditions are met. Sogroya should only be covered to treat children who are at least 2.5 ...
openaire +1 more source
A Pharmacological Profile of Somapacitan for the Treatment of Growth Hormone Deficiency
Expert Review of Clinical PharmacologyLong-acting growth hormone (LAGH) preparations have been developed to reduce the burden of daily injections and improve compliance in children and adults with growth hormone deficiency (GHD). Somapacitan is the only LAGH approved for both pediatric and adult GHD that has been in the market for nearly 2 years for these indications.
Heba Al-Rayess, Bradley Miller
exaly +3 more sources
Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency
Drugs of Today, 2022Growth hormone deficiency (GHD) is characterized by inadequate HG production from the anterior pituitary gland. Adult patients with GHD have increased fat mass, an abnormal lipid profile, decreased lean body mass and bone mineral density, decreased muscle strength and exercise endurance, and a diminished quality of life.
openaire +2 more sources
Efficacy, Safety, and Insulin-Like Growth Factor I of Weekly Somapacitan in Children With Growth Hormone Deficiency: 3-Year Results From REAL4 [PDF]
European Journal of EndocrinologyObjective: Somapacitan is a long-acting GH approved for once-weekly treatment of GH deficiency (GHD). This study aims to evaluate the efficacy and tolerability of somapacitan after 3 years of treatment and 2 years after switch from daily GH in children ...
Jun Mori +2 more
exaly +2 more sources
Growth Hormone & IGF Research, 2017
Somapacitan is an albumin-binding growth hormone derivative intended for once weekly administration, currently in clinical development for treatment of adult as well as juvenile GH deficiency. Nonclinical in vivo pharmacological characterisation of somapacitan was performed to support the clinical trials.
Peter, Thygesen +6 more
openaire +2 more sources
Somapacitan is an albumin-binding growth hormone derivative intended for once weekly administration, currently in clinical development for treatment of adult as well as juvenile GH deficiency. Nonclinical in vivo pharmacological characterisation of somapacitan was performed to support the clinical trials.
Peter, Thygesen +6 more
openaire +2 more sources